COVID-19

NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates

Landmark Phase 1a/2b clinical trial of NVG-291 proceeds with recruitment of individuals with spinal cord injury; results expected in mid-2024…

2 years ago

Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption

The Collaboration Signals Era of New Innovation for AI Nose Technology for Broader Industry AdoptionWith Partnership, Ainos Makes Progress Towards…

2 years ago

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Management will present and hold virtual 1-on-1 meetings with institutional investors and analystsCompany recently announced license and collaboration expansions for…

2 years ago

NHI Announces Second Quarter 2023 Results

MURFREESBORO, TN / ACCESSWIRE / August 8, 2023 / National Health Investors, Inc. (NYSE:NHI) announced today its results for the…

2 years ago

NHI Announces Third Quarter 2023 Dividend

MURFREESBORO, TN / ACCESSWIRE / August 8, 2023 / National Health Investors, Inc. (NYSE:NHI) announced today that it will pay…

2 years ago

NHI Issues Investor Update

MURFREESBORO, TN / ACCESSWIRE / August 8, 2023 / National Health Investors, Inc. (NYSE:NHI) has issued the following investor update…

2 years ago

Dr. Eric Beck Succeeds ESO Founder Chris Dillie as CEO

Beck joined the company as president in 2022AUSTIN, Texas--(BUSINESS WIRE)--ESO, the leading data and software company serving emergency medical services…

2 years ago

Hemostemix Submits Its Retrospective Heart Study to Leading Stem Cell Journal and Has Prepared Its CLI Phase II Clinical Trial Manuscript for Peer Review

Calgary, Alberta--(Newsfile Corp. - August 8, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce…

2 years ago

Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor

CHICAGO, IL / ACCESSWIRE / August 8, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global…

2 years ago

NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval

Recruitment of individuals with spinal cord injury (SCI) initiated at Shirley Ryan AbilityLab in ChicagoChronic SCI cohort results expected in…

2 years ago